HT on Nature journal
Precision medicine is at the heart of the future development of European healthcare. This is the indication of a roadmap presented by LifeTime ,the European consortium which sees HT amongs its associate partners.
The journal Nature published the article “LifeTime and improving European healthcare through cell-based interceptive medicine”. In the article innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime. A united vision to revolutionise healthcare.
Prof. Giuseppe Testa, Head of Research Centre for Neurogenomics, member of the Lifetime steering committee and co-authore of the report, commented: “LifeTime represents the best of the European spirit, which from frontier research on the cellular basis of human diseases now has the opportunity to gain concrete experience in the lives of patients and in the sustainability of our health systems. The pandemic reminded us of our fragility. Transforming healthcare through a precise understanding of the mechanisms by which a disease begins and develops over time in each patient remains an enormous challenge. But today we are finally beginning to see its feasibility thanks to a new research model that places the clinic at the center of three technological frontiers: organoids, models of each patient’s diseased organs, associated with the ability to analyze them over time, cell by cell, in all their dimensions, also making use of artificial intelligence. We are preparing to choose how to project our country towards rebirth through the Recovery Fund. LifeTime in this sense is a trace of how to do it, in the biomedical field, of how to open the future while remaining anchored to the needs of today that have never before appeared to us with so much drama.”
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.